Clindamycin/tretinoin: Clindamycin phosphate/tretinoin gel

Drugs in R and D

Volumn 6, Issue 4, 2005, Pages 231-234

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABERELA; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; CLINDAMYCIN PLUS RETINOIC ACID; RETINOIC ACID;

ACNE; ACNE VULGARIS; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AQUEOUS SOLUTION; BURNING SENSATION; CANADA; CLINICAL TRIAL; COMMERCIAL PHENOMENA; DESQUAMATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; FRANCE; GEL; HUMAN; INJECTION SITE REACTION; LICENSING; MARKET; MEXICO; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN IRRITATION; SKIN MANIFESTATION; UNITED STATES; XEROSIS;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CLINDAMYCIN; CLINICAL TRIALS, PHASE III; DRUG COMBINATIONS; DRUGS, INVESTIGATIONAL; GELS; HUMANS; KERATOLYTIC AGENTS; TRETINOIN;

EID: 22244437611     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506040-00006     Document Type: Review

References (13)

1. Connetics Corporation. Connetics Licenses Velac(R) Gel From Yamanouchi. Media Release: 14 May 2002. Available from URL: http://www.connetics.com
2. Connetics Corporation. Connetics Announces Positive Results from Velac Phase III Pivotal Trials. Media Release: 23 Mar 2004. Available from URL: http://www.connetics.com
3. Connetics Corporation. Connetics Affirms Velac Patent Position. Media Release: 22 Nov 2004. Available from URL: http://www.connetics.com
4. Connetics Corporation. Connetics' New Drug Application for Velac(R) Has Been Accepted for Filing by the FDA. Media Release: 25 Oct 2004. Available from URL: http://www.connetics.com
5. Connetics Corporation. Connetics Presents 11 Scientific Posters at American Academy of Dermatology's 62nd Annual Meeting. Media Release: 6 Feb 2004. Available from URL: http://www.connetics.com
6. van Hoogdalem EJ, Terpstra IJ, Spiegel-Melsen D. Absorption of clindamycin and tretinoin from topically applied anti-acne formulations in man. European Journal of Clinical Pharmacology 52 (Suppl.): 152, 1997
7. Richter JR, Bousema MT, De Boulle KLVM. Efficacy of a fixed clindamycin phosphate 1.2%, tretinoin 0.025% gel formulation (Velac) in the topical control of facial acne lesions. Journal of Dermatological Treatment 9: 81-90, Jun 1998
8. Zouboulis ChC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac Rm) applied once daily and a clindamycin lotion formulation (Dalacin T Rm) applied twice daily in the topical treatment of acne vulgaris. British Journal of Dermatology 143: 498-505, Sep 2000
9. Yaroshinsky A, Leyden J. The safety and efficacy of clindamycin [1% as clindamycin phosphate and tretinoin (0.025%)] for the treatment of acne vulgaris: a combined analysis of results from six controlled safety and efficacy trials conducted in Europe. Journal of the American Academy of Dermatology 50 (Suppl.): 23 (plus poster) abstr. P89, No. 3, Mar 2004
10. Leyden J, Yaroshinsky A, Krochmal L. Tolerability assessment of combination clindamycin/tretinoin hydrogel for the treatment of acne vulgaris in 2219 subjects. Journal of the American Academy of Dermatology 52 (Abstr. Suppl.): 25, No. 3, Mar 2005
11. Krochmal L, Yaroshinsky A. The novel combination clindamycin/tretinoin hydrogel: a randomized, double-blind, active- and vehicle-controlled study. Journal of the American Academy of Dermatology 52 (Abstr. Suppl.): 23 (+ poster), No. 3, Mar 2005
12. Yaroshinsky A, Krochmal L. Acne treatment outcomes with a once-daily combination of clindamycin and tretinoin in hydrogel compared with single agents. Journal of the American Academy of Dermatology 52 (Abstr. Suppl.): 26 (plus poster) abstr. P163, No. 3, Mar 2005
13. Leyden J, Yaroshinsky A, Krochmal L. Two randomized, controlled trials of a combination clindamycin/tretinoin hydrogel, compared with each agent alone for the tratment of acne vulgaris in 2219 subjects. Journal of the American Academy of Dermatology 52 (Abstr. Suppl.): 25 (plus poster), No. 3, Mar 2005